Teleflex Incorporated (NYSE:TFX) is set to announce its earnings results before the market opens on Thursday, November 2nd. Analysts expect the company to announce earnings of $2.00 per share for the quarter. Teleflex has set its FY17 guidance at $8.20-8.35 EPS.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, beating the Zacks’ consensus estimate of $1.91 by $0.13. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The company had revenue of $528.60 million for the quarter, compared to analyst estimates of $518.98 million. During the same quarter last year, the firm posted $1.89 earnings per share. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, analysts expect Teleflex to post $8.29 EPS for the current fiscal year and $9.62 EPS for the next fiscal year.

Teleflex Incorporated (NYSE TFX) opened at 242.43 on Thursday. The company has a market cap of $10.92 billion, a price-to-earnings ratio of 46.36 and a beta of 1.07. The company’s 50-day moving average is $239.52 and its 200-day moving average is $213.89. Teleflex Incorporated has a 12 month low of $136.53 and a 12 month high of $248.68.

In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $211.75, for a total transaction of $42,350.00. Following the transaction, the director now owns 8,080 shares in the company, valued at approximately $1,710,940. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 600 shares of company stock worth $132,408. 2.39% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This story was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at

A number of research firms recently weighed in on TFX. Needham & Company LLC increased their price target on Teleflex from $228.00 to $237.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. Morgan Stanley upgraded Teleflex from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $220.00 to $274.00 in a research note on Wednesday, September 6th. KeyCorp restated a “hold” rating on shares of Teleflex in a research note on Wednesday, September 6th. Jefferies Group LLC restated a “buy” rating and issued a $253.00 price target (up previously from $230.00) on shares of Teleflex in a research note on Wednesday, August 9th. Finally, Barclays PLC restated an “overweight” rating and issued a $253.00 price target (up previously from $230.00) on shares of Teleflex in a research note on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $260.75.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with's FREE daily email newsletter.